High expertise, high knowledge...
Technology & Products
Promethera® biosciences’ technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: human Adult Liver-Derived Mesenchymal progenitor/Stem cell (hALDMSC). Promethera® biosciences has developed an innovative technology to isolate and expand the progenitor cell type in order to develop two products: Promethera® HepaStem and Promethera® HepaScreen.
Promethera® HepaStem is a therapeutic product designed to treat liver diseases by allogeneic liver injection of hALDMSC.
- This product has received two orphan drug designations from the European Community for the treatment of Crigler-Najjar syndrome and the treatment of Ornithine transcarbamylase deficiency, an urea cycle disease.
Please click below to get access to a video describing The therapeutic road of HEPASTEM, a unique liver progenitor cell-based therapy.
Promethera® HepaScreen is a biotechnology tool designed for metabolic evaluation of new chemical entities.
- In vitro differentiated hALDMSC express most of the hepatic markers and functions that could be used by the pharmaceutical companies to evaluate liver metabolism or toxicity of newly synthesized compounds during screening or lead compound optimization.
Pipeline
Table below presents Promethera Biosciences' Pipeline in February 2011.
Contacts
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
(Belgium)
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01
